In the last trading session, 1.12 million Trevi Therapeutics Inc (NASDAQ:TRVI) shares changed hands as the company’s beta touched 0.92. With the company’s per share price at $4.52 changed hands at $0.21 or 4.87% during last session, the market valuation stood at $403.94M. TRVI’s last price was a discount, traded about -11.73% off its 52-week high of $5.05. The share price had its 52-week low at $2.30, which suggests the last value was 49.12% up since then.
Analysts gave the Trevi Therapeutics Inc (TRVI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.09. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TRVI as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Trevi Therapeutics Inc’s EPS for the current quarter is expected to be -0.11.
Trevi Therapeutics Inc (NASDAQ:TRVI) trade information
Instantly TRVI was in green as seen at the end of in last trading. With action 7.11%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 9.71%, with the 5-day performance at 7.11% in the green. However, in the 30-day time frame, Trevi Therapeutics Inc (NASDAQ:TRVI) is 15.60% up.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 24.67% from its current market value. According to analyst projections, TRVI’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -32.74% plunge from its current level, while the stock would need to soar -32.74% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 27.24%. The 2025 estimates are for Trevi Therapeutics Inc earnings to decrease by -73.55%, but the outlook for the next 5-year period is at -27.58% per year.
TRVI Dividends
Trevi Therapeutics Inc is expected to release its next quarterly earnings report in March.
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 7.305% or 7.38 million shares worth $22.0 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 1.78 shares estimated at $8.02 million under it, the former controlled 2.31% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.97% of the shares, roughly 1.52 shares worth around $6.86 million.
